View printer-friendly version |
Charles River Announces First-Quarter 2009 Results
First-Quarter Sales Decrease 11% to $302 Million
On a GAAP basis, net income for the first quarter of 2009 was
On a non-GAAP basis, net income was
First-Quarter Segment Results
Research Models and Services (RMS)
Sales for the RMS segment were
Lower sales volume and higher operating costs related to new capacity
brought on line in
Preclinical Services (PCS)
First-quarter 2009 net sales for the PCS segment were
As expected, lower capacity utilization, pricing pressure and costs
associated with the start-up of new facilities in
Items Excluded from Non-GAAP Results
Items excluded from non-GAAP results in the first quarter of 2009 and 2008 are as follows:
($ in millions) | 1Q09 | 1Q08 | ||||
Amortization of intangible assets | $ | 6.1 | $ | 7.6 | ||
Severance related to cost-saving actions | 7.1 | -- | ||||
Impairment and other charges (1) | 1.6 | 0.7 | ||||
Operating losses for PCS Arkansas and clinical Phase I Scotland | 1.5 | -- | ||||
SFAS No. 141(R) (Costs associated with evaluation of acquisitions) | 0.2 | -- | ||||
FSP No. APB 14-1 (Convertible debt accounting) | 2.4 | 1.8 |
(1) In the first quarter of 2009, these items were related primarily to
an asset impairment charge associated with the Company’s planned
divestiture of its clinical Phase I business in
2009 Guidance
The Company reaffirms its forward-looking guidance for 2009, which was
originally provided on
2009 GUIDANCE | ||
Net sales | (2)% - (7)% | |
GAAP EPS estimate | $1.86 - $2.16 | |
Amortization of intangible assets | $0.27 | |
Severance related to cost-saving actions | $0.08 | |
Impairment and other charges | $0.02 | |
Operating losses for PCS Arkansas and clinical Phase I Scotland | $0.04 | |
FSP No. APB 14-1 (Convertible debt accounting) | $0.11 | |
Non-GAAP EPS estimate | $2.30 - $2.60 |
Acquisition of
On
Webcast
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, such as
non-GAAP earnings per diluted share, which exclude amortization of
intangible assets and other charges related to our acquisitions, charges
related to the dispositions of our clinical Phase I business in
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “anticipate,”
“believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and
“project” and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters. These
statements also include statements regarding our projected 2009 sales
and earnings; the future demand for drug discovery and development
products and services (particularly in light of the challenging economic
environment), including the outsourcing of these services and present
spending trends by our customers; the impact of specific actions
intended to improve overall operating efficiencies and profitability;
the timing of the opening of new and expanded facilities by us and our
competitors; our future stock purchase activities; future cost reduction
activities by our customers; and Charles River’s future performance as
delineated in our forward-looking guidance, and particularly our
expectations with respect to sales growth and foreign exchange impact.
In addition, these statements include the availability of funding for
our customers and the impact of economic and market conditions on them
generally, and the anticipated strength of our balance sheet, the
effects of our first-quarter 2009 cost-saving actions and other actions
designed to manage expenses, operating costs and capital spending, and
to streamline efficiency, and the ability of the Company to withstand
the current market conditions. Forward-looking statements are based on
Charles River’s current expectations and beliefs, and involve a number
of risks and uncertainties that are difficult to predict and that could
cause actual results to differ materially from those stated or implied
by the forward-looking statements. Those risks and uncertainties
include, but are not limited to: the ability to successfully integrate
the acquisition of the business and assets of
About Charles River
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our approximately 8,700 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) | |||||||
(dollars in thousands, except for per share data) | |||||||
Three Months Ended | |||||||
March 28, | March 29, | ||||||
2009 | 2008 | ||||||
Total net sales | $ | 301,526 | $ | 337,685 | |||
Cost of products sold and services provided | 193,306 | 207,308 | |||||
Gross margin | 108,220 | 130,377 | |||||
Selling, general and administrative | 62,178 | 59,320 | |||||
Amortization of intangibles | 6,149 | 7,571 | |||||
Operating income | 39,893 | 63,486 | |||||
Interest income (expense) | (4,604 | ) | (2,410 | ) | |||
Other income (expense) | (262 | ) | (837 | ) | |||
Income before income taxes and noncontrolling interests | 35,027 | 60,239 | |||||
Provision for income taxes | 10,158 | 16,183 | |||||
Income before noncontrolling interests | 24,869 | 44,056 | |||||
Noncontrolling interests | 536 | 83 | |||||
Net income | $ | 25,405 | $ | 44,139 | |||
Earnings per common share | |||||||
Basic | $ | 0.39 | $ | 0.65 | |||
Diluted | $ | 0.38 | $ | 0.63 | |||
Weighted average number of common shares outstanding | |||||||
Basic | 65,889,835 | 67,504,848 | |||||
Diluted | 66,020,082 | 70,559,456 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |||||
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | |||||
(dollars in thousands) | |||||
March 28, | December 27, | ||||
2009 | 2008 | ||||
Assets | |||||
Current assets | |||||
Cash and cash equivalents | $ | 170,233 | $ | 243,592 | |
Trade receivables, net | 211,095 | 210,214 | |||
Inventories | 97,560 | 96,882 | |||
Other current assets | 102,576 | 67,218 | |||
Current assets of discontinued businesses | 256 | 233 | |||
Total current assets | 581,720 | 618,139 | |||
Property, plant and equipment, net | 834,545 | 837,246 | |||
Goodwill, net | 454,770 | 457,578 | |||
Other intangibles, net | 126,914 | 136,100 | |||
Deferred tax asset | 34,617 | 37,348 | |||
Other assets | 50,835 | 50,815 | |||
Long-term assets of discontinued businesses | 4,187 | 4,187 | |||
Total assets | $ | 2,087,588 | $ | 2,141,413 | |
Liabilities and Shareholders’ Equity | |||||
Current liabilities | |||||
Current portion of long-term debt & capital leases | $ | 35,376 | $ | 35,452 | |
Accounts payable | 37,280 | 40,517 | |||
Accrued compensation | 41,425 | 54,870 | |||
Deferred revenue | 83,689 | 86,707 | |||
Accrued liabilities | 55,167 | 60,741 | |||
Other current liabilities | 26,889 | 22,676 | |||
Current liabilities of discontinued businesses | 47 | 35 | |||
Total current liabilities | 279,873 | 300,998 | |||
Long-term debt & capital leases | 474,152 | 479,880 | |||
Other long-term liabilities | 115,525 | 118,827 | |||
Total liabilities | 869,550 | 899,705 | |||
Total shareholders’ equity | 1,218,038 | 1,241,708 | |||
Total liabilities and shareholders’ equity | $ | 2,087,588 | $ | 2,141,413 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) | ||||||||
(dollars in thousands) | ||||||||
Three Months Ended | ||||||||
March 28, | March 29, | |||||||
2009 | 2008 | |||||||
Research Models and Services | ||||||||
Net sales | $ | 161,490 | $ | 168,596 | ||||
Gross margin | 68,313 | 76,256 | ||||||
Gross margin as a % of net sales | 42.3 | % | 45.2 | % | ||||
Operating income | 47,444 | 55,813 | ||||||
Operating income as a % of net sales | 29.4 | % | 33.1 | % | ||||
Depreciation and amortization | 7,673 | 6,666 | ||||||
Capital expenditures | 7,624 | 10,609 | ||||||
Preclinical Services | ||||||||
Net sales | $ | 140,036 | $ | 169,089 | ||||
Gross margin | 39,907 | 54,121 | ||||||
Gross margin as a % of net sales | 28.5 | % | 32.0 | % | ||||
Operating income | 10,546 | 23,268 | ||||||
Operating income as a % of net sales | 7.5 | % | 13.8 | % | ||||
Depreciation and amortization | 14,297 | 15,681 | ||||||
Capital expenditures | 17,001 | 30,021 | ||||||
Unallocated Corporate Overhead | $ | (18,097 | ) | $ | (15,595 | ) | ||
Total | ||||||||
Net sales | $ | 301,526 | $ | 337,685 | ||||
Gross margin | 108,220 | 130,377 | ||||||
Gross margin as a % of net sales | 35.9 | % | 38.6 | % | ||||
Operating income | 39,893 | 63,486 | ||||||
Operating income as a % of net sales | 13.2 | % | 18.8 | % | ||||
Depreciation and amortization | 21,970 | 22,347 | ||||||
Capital expenditures | 24,625 | 40,630 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |||||||||
RECONCILIATION OF GAAP TO NON-GAAP | |||||||||
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1) | |||||||||
(dollars in thousands) | |||||||||
Three Months Ended | |||||||||
March 28, | March 29, | ||||||||
2009 | 2008 | ||||||||
Research Models and Services | |||||||||
Net sales | $ | 161,490 | $ | 168,596 | |||||
Operating income | 47,444 | 55,813 | |||||||
Operating income as a % of net sales | 29.4 | % | 33.1 | % | |||||
Add back: | |||||||||
Amortization related to acquisitions | 887 | 534 | |||||||
Severance | 2,709 | - | |||||||
Operating income, excluding specified charges (Non-GAAP) | $ | 51,040 | $ | 56,347 | |||||
Non-GAAP operating income as a % of net sales | 31.6 | % | 33.4 | % | |||||
Preclinical Services | |||||||||
Net sales | $ | 140,036 | $ | 169,089 | |||||
Operating income | 10,546 | 23,268 | |||||||
Operating income as a % of net sales | 7.5 | % | 13.8 | % | |||||
Add back: | |||||||||
Amortization related to acquisitions | 5,261 | 7,037 | |||||||
Severance | 2,776 | - | |||||||
Impairment and other charges (2) | 1,527 | 686 | |||||||
Operating losses for PCS Arkansas and Phase I Scotland | 1,543 | - | |||||||
Operating income, excluding specified charges (Non-GAAP) | $ | 21,653 | $ | 30,991 | |||||
Non-GAAP operating income as a % of net sales | 15.5 | % | 18.3 | % | |||||
Unallocated Corporate Overhead | $ | (18,097 | ) | $ | (15,595 | ) | |||
Add back: | |||||||||
Severance | 1,648 | - | |||||||
Impairment and other charges (2) | 97 | - | |||||||
SFAS No. 141(R) (costs associated with the evaluation of acquisitions) | 229 | - | |||||||
FSP No. APB 14-1 (convertible debt accounting) (3) | 44 | 14 | |||||||
Unallocated corporate overhead, excluding specified charges (Non-GAAP) | $ | (16,079 | ) | $ | (15,581 | ) | |||
Total | |||||||||
Net sales | $ | 301,526 | $ | 337,685 | |||||
Operating income | 39,893 | 63,486 | |||||||
Operating income as a % of net sales | 13.2 | % | 18.8 | % | |||||
Add back: | |||||||||
Amortization related to acquisitions | 6,148 | 7,571 | |||||||
Severance | 7,133 | - | |||||||
Impairment and other charges (2) | 1,624 | 686 | |||||||
Operating losses for PCS Arkansas and Phase I Scotland | 1,543 | - | |||||||
SFAS No. 141(R) (costs associated with the evaluation of acquisitions) | 229 | - | |||||||
FSP No. APB 14-1 (convertible debt accounting) (3) | 44 | 14 | |||||||
Operating income, excluding specified charges (Non-GAAP) | $ | 56,614 | $ | 71,757 | |||||
Non-GAAP operating income as a % of net sales | 18.8 | % | 21.2 | % | |||||
(1) | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. | ||||||||
(2) | 2009 includes an asset impairment due to the anticipated sale of our clinical Phase I business in Scotland, as well as additional miscellaneous costs. 2008 includes the disposition of the Company's Preclinical Services facility in Worcester, Massachusetts. | ||||||||
(3) | 2009 and 2008 include the impact of FSP No. APB 14-1 for convertible debt accounting, which increased depreciation expense. |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |||||
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (1) | |||||
(dollars in thousands, except for per share data) | |||||
Three Months Ended | |||||
March 28, | March 29, | ||||
2009 | 2008 | ||||
Net income | $ 25,405 | $ 44,139 | |||
Add back: | |||||
Amortization related to acquisitions | 6,148 | 7,571 | |||
Severance | 7,133 | - | |||
Impairment and other charges (2) | 1,624 | 686 | |||
Operating losses for PCS Arkansas and Phase I Scotland | 1,543 | - | |||
SFAS No. 141(R) (costs associated with the evaluation of acquisitions) | 229 | - | |||
FSP No. APB 14-1 (convertible debt accounting), net (3) | 2,397 | 1,758 | |||
Tax effect | (6,289) | (3,348) | |||
Net income, excluding specified charges (Non-GAAP) | $ 38,190 | $ 50,806 | |||
Weighted average shares outstanding - Basic | 65,889,835 | 67,504,848 | |||
Effect of dilutive securities: | |||||
2.25% senior convertible debentures | - | 1,421,424 | |||
Stock options and contingently issued restricted stock | 126,896 | 1,363,212 | |||
Warrants | 3,351 | 269,972 | |||
Weighted average shares outstanding - Diluted | 66,020,082 | 70,559,456 | |||
Basic earnings per share | $ 0.39 | $ 0.65 | |||
Diluted earnings per share | $ 0.38 | $ 0.63 | |||
Basic earnings per share, excluding specified charges (Non-GAAP) | $ 0.58 | $ 0.75 | |||
Diluted earnings per share, excluding specified charges (Non-GAAP) | $ 0.58 | $ 0.72 | |||
(1) | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. | ||||
(2) | 2009 includes an asset impairment due to the anticipated sale of our clinical Phase I business in Scotland, as well as additional miscellaneous costs. 2008 includes the disposition of the Company's Preclinical Services facility in Worcester, Massachusetts. | ||||
(3) | 2009 includes the impact of FSP No. APB 14-1 for convertible debt accounting, which increased interest expense by $2,860, capitalized interest by $507 and depreciation expense by $44. 2008 has been restated to include the impact of FSP No. APB 14-1, which increased interest expense by $2,670, capitalized interest by $926 and depreciation expense by $14. |
Source:
Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Associate Director,
Public Relations